Prostate cancer: Are new prognostic markers on the horizon?

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 2, 2000, Pages 62-65

  Lijovic, M ^a   Fabiani, M E ^a   Bader, J ^a   Frauman, A G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Metastasis; Metastasis suppressor genes; Neoplasia; Prognostic markers; Prostate; Prostate cancer

Indexed keywords

HERMES ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UVOMORULIN;

ANTIGEN EXPRESSION; CANCER GRADING; EXTRACELLULAR MATRIX; HUMAN; MALE; MALE GENITAL TRACT CANCER; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033837340     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500408     Document Type: Review

References (49)

1. Cancer statistics
2. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens
3. Correlation between Gleason score of needle biopsy and radical prostatectomy tissue
4. Biopsy Gleason score: How does it correlate with the final pathological diagnosis in prostate cancer?
5. Neoplasms of the prostate
6. Genetic aspects of prostate cancer
7. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis
8. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
9. Evaluation of changes in PSA in the management of men with prostate cancer
10. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
11. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
12. Analysis of variation in prostate-specific antigen values
13. Prostate intervention versus observation trial (PVOT): A randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT planning committee
14. The Prostate Cancer Intervention Versus Observation Trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer
15. Molecular biology of prostate development and prostate cancer
16. Molecular genetics and epidemiology of prostate carcinoma
17. Molecular biologic aspects of human prostatic cardnoma
18. Molecular advances in prostate cancer
19. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
20. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate cardnoma
21. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer
22. Modulation of oncogenic potential by alternative gene use in human prostate cancer
23. Prostate cancer prevention: Investigational approaches and opportunities
24. The use of cell fusion to analyse factors involved in tumour cell metastasis
25. Cell fusion segregates progressive growth from metastasis
26. Selective suppression of metastasis but not tumorigenicity of a mouse lung cardnoma by cell hybridization
27. Expression of collagenase IV (basement membrane collagense) activity in murine tumor cell hybrids that differ in metastatic potential
28. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer
29. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer
30. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
31. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
32. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: A biphasic relationship with tumour grade
33. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
34. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells
35. Prostate cancer prevention: Investigational approaches and opportunities
36. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: Correlation with patient survival
37. Expression of E-cadherin in primary and metastatic prostate cancer
38. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
39. Decreased expression of E-cadherin in the progression of rat prostatic cancer
40. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11 p13
41. Altered expression of CD44 in human prostate cancer during progression
42. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy
43. Quantitation of NM23 expression in human prostate tissues
44. NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: Altered expression in combined androgen blockaded carcinomas
45. Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate
46. High levels of nm23 expression are related to cell proliferation in human prostate cancer
47. Expression of nm23-H1 in prostatic intraepithelial neoplasia and adenocarcinoma
48. Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy
49. Thymosin beta 15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer